Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Amcor PLC (AMCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Amcor PLC — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.71 (market cap $5.07B), while Amcor PLC trades at $46.76 (market cap $21.92B). The key difference: Amcor PLC is far larger — about 4.3× ACADIA Pharmaceuticals Inc.'s market cap, and Amcor PLC pays a 5.49% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AMCR | |
|---|---|---|
Market Cap | $5.07B | $21.92B |
Sector | Health | Basic Materials |
52-Week High | $29.41 | $50.58 |
52-Week Low | $20.06 | $36.69 |
Enterprise Value | $4.19B | $37.03B |
Dividend Yield | — | 5.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
AMCR trades at $47.11, down 1.57% today, near the consensus price target of $47.00. Recent quarters show consistent earnings beats, with Q4 2026 revenue up 26% year-over-year to $6.4 billion, driven by the Berry acquisition (PRNewsWire, Aug 12, 2026). Technical indicators signal a bullish trend, while valuation ratios like P/E of 38.07 appear elevated relative to historical margins. The company maintains a solid dividend, with a $0.65 payment scheduled for June 2026.
Outlook is cautiously optimistic given strong revenue growth and analyst buy ratings (64% consensus), but risks include high debt levels and margin pressure, with net income margin declining to 3.06% in 2025. Investors should weigh acquisition benefits against integration challenges and cyclical demand headwinds in packaging markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →
